Werewolf Therapeutics, Inc. (HOWL) has a negative trailing P/E of -0.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -141.07%.
Criteria proven by this page:
Overall SharesGrow Score: 37/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -42.0 | 0.00 | 47.24 | 0.00 | - |
| 2020 | -30.9 | -0.20 | 5.17 | 0.00 | - |
| 2021 | -4.4 | 0.00 | 1.44 | 0.00 | - |
| 2022 | -1.1 | 0.01 | 0.48 | 3.61 | - |
| 2023 | -3.7 | 0.08 | 1.24 | 6.90 | - |
| 2024 | -0.9 | -0.02 | 0.87 | 34.02 | - |
| 2025 | -0.5 | 0.03 | 1.18 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.38 | $0.00 | $-10.99M | - |
| 2020 | $-0.52 | $0.00 | $-14.94M | - |
| 2021 | $-1.82 | $0.00 | $-49.77M | - |
| 2022 | $-1.79 | $16.4M | $-51.56M | -314.4% |
| 2023 | $-1.05 | $19.94M | $-37.37M | -187.4% |
| 2024 | $-1.61 | $1.89M | $-70.52M | -3740.8% |
| 2025 | $-1.33 | $0.00 | $-60.82M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.89 | $-1.18 – $-0.61 | $8.33M | $8.33M – $8.33M | 3 |
| 2027 | $-1.60 | $-2.19 – $-0.99 | $3.1M | $3.1M – $3.1M | 2 |
| 2028 | $-1.47 | $-2.18 – $-0.95 | $50K | $50K – $50K | 3 |
| 2029 | $-0.99 | $-0.99 – $-0.99 | $18M | $18M – $18M | 1 |
